keyword
MENU ▼
Read by QxMD icon Read
search

Daily hemodialysis

keyword
https://www.readbyqxmd.com/read/27905676/association-between-daily-hemodialysis-access-to-renal-transplantation-and-patients-survival-in-france
#1
Adélaïde Pladys, Cécile Vigneau, Maryvonne Hourmant, Gabrielle Duneau, Cécile Couchoud, Sahar Bayat
AIM: Daily hemodialysis improves patients' quality of life and blood purification, but its effect on survival remains controversial. The aim of this study was to analyze the association between daily hemodialysis and renal transplantation and survival in France. METHODS: This was an observational cohort study based on the French REIN registry. All incident patients ≥18 y/o who started daily hemodialysis in France between 2003 and 2012 were included. Using a propensity score, 575 patients on daily hemodialysis were matched with 1696 patients receiving thrice-weekly hemodialysis...
December 1, 2016: Nephrology
https://www.readbyqxmd.com/read/27904000/effects-of-flaxseed-oil-on-serum-lipids-and-lipoproteins-in-hemodialysis-patients-a-randomized-controlled-trial
#2
Maryam Mirfatahi, Hadi Tabibi, Alireza Nasrollahi, Mehdi Hedayati
INTRODUCTION: One of the major risk factors for cardiovascular disease is lipid abnormalities among hemodialysis patients. The present study was designed to investigate the effects of flaxseed oil consumption on serum lipids and lipoproteins in hemodialysis patients. MATERIALS AND METHODS: In a randomized double-blinded controlled trial, 34 hemodialysis patients were assigned to either the flaxseed oil or the control group. The patients in the flaxseed oil group received 6 g/d of flaxseed oil for 8 weeks, whereas the control group received 6 g/d of medium chain triglycerides oil...
November 2016: Iranian Journal of Kidney Diseases
https://www.readbyqxmd.com/read/27900441/successful-afatinib-treatment-of-advanced-non-small-cell-lung-cancer-patients-undergoing-hemodialysis
#3
Hisao Imai, Kyoichi Kaira, Ichiro Naruse, Hideki Hayashi, Hirotoshi Iihara, Yutaro Kita, Naoki Mizusaki, Takayuki Asao, Yoshinori Itoh, Tadashi Sugiyama, Koichi Minato, Masanobu Yamada
The treatment for patients with lung cancer undergoing hemodialysis, who are frequently elderly and have poor performance status, becomes a more important subject. However, the feasibility of afatinib in patients with chronic renal failure undergoing hemodialysis has not, so far, been reported. Here, afatinib was administered to three patients with NSCLC harboring EGFR mutation and chronic renal failure undergoing hemodialysis. Pharmacokinetic (PK) data of afatinib supported the safety of afatinib treatment...
November 29, 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27896236/the-effect-of-bcaa-and-iso-whey-oral-nutritional-supplements-on-dialysis-adequacy
#4
Effat Afaghi, Ali Tayebi, Abbas Ebadi, Vahid Sobhani, Behzad Einollahi, Mehdi Tayebi
BACKGROUND: Protein-energy malnutrition is a common problem in hemodialysis patients and has different outcomes such as reduced quality of life, longer hospitalization time, lower dialysis adequacy, and higher mortality rate. Investigation of dialysis adequacy is an important method for assessing hemodialysis patients, and improving the dialysis adequacy is an important healthcare team goal. OBJECTIVES: The present study aims to investigate and compare the effects of BCAA and ISO-WHEY oral nutritional supplements on dialysis adequacy...
November 2016: Nephro-urology Monthly
https://www.readbyqxmd.com/read/27885786/effects-of-flaxseed-oil-on-blood-hepcidin-and-hematologic-factors-in-hemodialysis-patients
#5
Hadi Tabibi, Maryam Mirfatahi, Mehdi Hedayati, Alireza Nasrollahi
Introduction In hemodialysis (HD) patients, one of the common complications is renal anemia. Therefore, the present study was designed to investigate the effects of flaxseed oil consumption on blood hepcidin and hematologic factors in HD patients. Methods In this randomized, double-blind, clinical trial, 38 HD patients were randomly assigned to either the flaxseed oil or the control group. The patients in the flaxseed oil group received 6 g/d flaxseed oil for 8 wk, whereas the control group received 6 g/d medium chain triglycerides (MCT) oil...
November 25, 2016: Hemodialysis International
https://www.readbyqxmd.com/read/27876356/-low-flux-dialysate-daily-home-hemodialysis-a-result-for-the-62%C3%A2-first-french-and-belgian-patients
#6
Anaïs Benabed, Patrick Henri, Thierry Lobbedez, Eric Goffin, Simona Baluta, Abdelkader Benziane, Ahmed Rachi, Johan W van der Pijl, Clémence Bechade, Maxence Ficheux
Since 2011, a new device is available for low flux dialysate quotidian home hemodialysis in France and Belgium. This study aims to evaluate the characteristics and dialysis prescriptions for Nx Stage System One™ users. We retrospectively included patients trained between 2011 and 2013 in France and Belgium. We collected data concerning their clinical features, their dialysis prescriptions, their laboratory parameters until 6 months of dialysis and, reason for dropping in case of cessation. Sixty-two patients from 31 centers, aged 48±18 years old, with a sex ratio 46/16 (M/F) are included with a median Charlson comorbidity index of 1 [0-3]...
November 18, 2016: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/27875005/asunaprevir-daclatasvir-and-sofosbuvir-ledipasuvir-for-recurrent-hepatitis-c-following-living-donor-liver-transplantation
#7
Kiyohiko Omichi, Nobuhisa Akamatsu, Kazuhiro Mori, Junichi Togashi, Junichi Arita, Junichi Kaneko, Kiyoshi Hasegawa, Yoshihiro Sakamoto, Norihiro Kokudo
AIM: This study aimed to clarify the efficacy and safety of interferon-free therapy using asunaprevir and daclatasvir, or sofosbuvir and ledipasuvir for post living donor liver transplantation (LDLT) recipients with hepatitis C virus (HCV). METHODS: A retrospective cohort study of LDLT recipients with HCV genotype 1b treated with asunaprevir (100 mg twice daily) and daclatasvir (60 mg once daily), or sofosbuvir (400 mg/day) and ledipasvir (90 mg/day) was conducted...
November 22, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27843749/mortality-markers-in-nosocomial-klebsiella-pneumoniae-bloodstream-infection
#8
Bulent Durdu, Ismail Necati Hakyemez, Sibel Bolukcu, Gulay Okay, Bilge Gultepe, Turan Aslan
PURPOSE: Klebsiella pneumoniae is the most common endogen agent for nosocomial infections. In this study, mortality markers were investigated in patients with nosocomial K. pneumoniae blood stream infection (NKp BSI). METHODS: The characteristics of patients >16 years who had NKp BSI diagnosis by daily active surveillance between January 2012 and January 2016 were retrospectively evaluated. Patients who died until 28th day of the clinical follow up and those who survived until this time were statistically compared in terms of various risk factors...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27825643/-sofosbuvir-and-daclatasvir-combination-therapy-in-hemodialysis-patient-with-liver-transplantation
#9
Mourad Hachicha, Danielle Botta-Fridlund
We report a case of sustained remission of a liver transplant patient infected with hepatitis C virus (HCV) genotype 1 undergoing hemodialysis treatment. Oral treatment regimen of the HCV infection consists of a combination of sofosbuvir 400 mg after each hemodialysis session and daclatasvir 60 mg daily, for a period of 3 months. Laboratory testing indicate that the combination regimen was well-tolerated with no sign of drug-drug interaction. Confirmation of these clinical observations in large clinical studies may help improve morbidity and decrease mortality outcome in patients infected with HCV and undergoing hemodialysis treatment...
November 4, 2016: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/27822564/design-of-a-randomized-controlled-clinical-trial-assessing-dietary-sodium-restriction-and-hemodialysis-related-symptom-profiles
#10
Maya N Clark-Cutaia, Marilyn S Sommers, Emily Anderson, Raymond R Townsend
AIM: In hemodialysis patients, the need to have intercurrent sodium and water intake removed by ultrafiltration increases disease burden through the symptoms and signs that occur during hemodialysis (HD). This added burden may be mitigated by reduction of dietary sodium intake. The National Kidney Foundation (NKF) recommends 2400 mg of dietary sodium daily for patients on HD, and the American Heart Association (AHA) suggests 1500 mg, evidence is lacking, however, to support these recommendations in HD...
August 15, 2016: Contemporary Clinical Trials Communications
https://www.readbyqxmd.com/read/27814946/phosphate-containing-prescription-medications-contribute-to-the-daily-phosphate-intake-in-a-third-of-hemodialysis-patients
#11
Seana M L Nelson, Samantha R S Sarabia, Erin Christilaw, Emilie C Ward, Stephanie K Lynch, Michael A Adams, Rachel M Holden
OBJECTIVES: Hyperphosphatemia is associated with all-cause mortality in hemodialysis (HD) patients and is managed by restricting dietary phosphate. Many patients are unable to adhere to the recommended dietary phosphate limit. We sought to quantify the additional phosphate burden from prescription medication in a hemodialysis population. DESIGN: Cross-sectional study. SUBJECTS: Adult patients on hemodialysis at a single center. SETTING: The Health Canada Drug Product Database was used to identify formulations of medications prescribed in an HD program that contain phosphate salts...
November 1, 2016: Journal of Renal Nutrition
https://www.readbyqxmd.com/read/27810689/efficacy-and-safety-of-teneligliptin-in-addition-to-insulin-therapy-in-type-2-diabetes-mellitus-patients-on-hemodialysis-evaluated-by-continuous-glucose-monitoring
#12
Takahiro Yajima, Kumiko Yajima, Makoto Hayashi, Hiroshi Takahashi, Keigo Yasuda
AIMS: Appropriate glycemic control without hypoglycemia is important in patients with type 2 diabetes on hemodialysis. Teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, can be used without dose adjustment for these patients. Using continuous glucose monitoring (CGM), we evaluated the efficacy and safety of adding teneligliptin to insulin therapy. METHODS: Twenty-one type 2 diabetes mellitus patients on hemodialysis treated with insulin were enrolled. After the adjustment of insulin dose, their blood glucose level was monitored by CGM...
October 21, 2016: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/27789113/baclofen-toxicity-in-a-patient-with-hemodialysis-dependent-end-stage-renal-disease
#13
Lauren M Porter, Stephanie S Merrick, Kenneth D Katz
BACKGROUND: Oral baclofen toxicity is extremely rare, but can affect patients with renal disease due to the drug's predominant renal clearance of approximately 69-85%. Patients with severely impaired renal function typically develop symptoms soon after initiating baclofen therapy, even at relatively low doses. CASE REPORT: A 69-year-old woman with a history of hemodialysis-dependent end-stage renal disease presented to the Emergency Department with encephalopathy, ataxia, and dystonia after the addition of a recent baclofen prescription for back pain (10 mg twice daily)...
October 24, 2016: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/27784004/patiromer-decreases-serum-potassium-and-phosphate-levels-in-patients-on-hemodialysis
#14
David A Bushinsky, Patrick Rossignol, David M Spiegel, Wade W Benton, Jinwei Yuan, Geoffrey A Block, Christopher S Wilcox, Rajiv Agarwal
BACKGROUND: Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is associated with increased mortality, and treatment options are limited. The effect of patiromer, a gastrointestinal K binder, on serum K was examined in HD patients. METHODS: Six hyperkalemic HD patients (5 anuric) were admitted to clinical research units for 15 days (1 pretreatment week and 1 patiromer treatment week) and they received a controlled diet with identical meals on corresponding days of pretreatment and treatment weeks...
2016: American Journal of Nephrology
https://www.readbyqxmd.com/read/27778458/t-wave-alternans-heart-rate-turbulence-and-ventricular-ectopy-in-standard-versus-daily-hemodialysis-results-from-the-fhn-daily-trial
#15
Rachel M Kaplan, Charles A Herzog, Brett Larive, Haris Subacius, Bruce D Nearing, Richard Verrier, Rod S Passman
BACKGROUND: Hemodialysis (HD) patients are at high risk of sudden cardiac death (SCD). HD 6-times/week (6x/wk) may reduce SCD risk compared to usual 3-times/week HD (3x/wk) by mechanisms unknown. T-wave alternans (TWA), heart rate turbulence (HRT), and ventricular ectopy (VE) are elevated in HD patients, but their response to 6x/wk HD has not been assessed. METHODS: Baseline and 1-year Holter recordings were analyzed from enrollees in the Frequent Hemodialysis Network Daily Trial, a randomized trial comparing 3x/wk to 6x/wk in 245 chronic HD patients...
November 2016: Annals of Noninvasive Electrocardiology
https://www.readbyqxmd.com/read/27777427/relationship-between-changes-in-physical-activity-and-changes-in-health-related-quality-of-life-in-patients-on-chronic-hemodialysis-with-1-year-follow-up
#16
Akihiko Katayama, Nobuyuki Miyatake, Hiroyuki Nishi, Kazuhiro Ujike, Hiroo Hashimoto, Risa Kurato, Kiichi Koumoto
In a longitudinal study, we examined the link between changes in physical activity and changes in health-related quality of life (HRQOL) in patients on chronic hemodialysis. Seventy-one patients (43 males, 28 females; aged 70.9±10.6 years) on chronic hemodialysis in September 2013 were enrolled. The data of the 43 patients whose complete measurements were taken again in September 2014 were used for the longitudinal analysis. Clinical parameters including age, height, dry weight, duration of hemodialysis, blood pressure (BP), blood triglyceride and HDL cholesterol levels, physical activity, and HRQOL were evaluated...
October 2016: Acta Medica Okayama
https://www.readbyqxmd.com/read/27776970/-evaluation-of-educational-interventions-with-dialysis-patient
#17
Matthieu Parmier, Bénédicte Gourieux, Thierry Krummel, Dorothée Bazin-Kara, Anne Dory, Thierry Hannedouche
The treatment of end-stage renal disease requires a significant number of drug treatments. At patient level, daily management is somewhat difficult: Number of prescribed pills, medication side effects, treatment of asymptomatic diseases… The objective of the study was to investigate the effect of guidance tailored to each patient receiving hemodialysis, performed by the pharmacist (educational interventions). Adult haemodialysis patients with hyperphosphatemia despite phosphate binders were eligible for study entry...
October 21, 2016: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/27774730/hyperprolactinemia-in-end-stage-renal-disease-and-effects-of-frequent-hemodialysis
#18
Joan C Lo, Gerald J Beck, George A Kaysen, Christopher T Chan, Alan S Kliger, Michael V Rocco, Glenn M Chertow
Introduction End-stage renal disease is associated with elevations in circulating prolactin concentrations, but the association of prolactin concentrations with intermediate health outcomes and the effects of hemodialysis frequency on changes in serum prolactin have not been examined. Methods The FHN Daily and Nocturnal Dialysis Trials compared the effects of conventional thrice weekly hemodialysis with in-center daily hemodialysis (6 days/week) and nocturnal home hemodialysis (6 nights/week) over 12 months and obtained measures of health-related quality of life, self-reported physical function, mental health and cognition...
October 23, 2016: Hemodialysis International
https://www.readbyqxmd.com/read/27772644/intensive-hemodialysis-and-potential-risks-with-increasing%C3%A2-treatment
#19
Michael A Kraus, Sheru Kansal, Michael Copland, Paul Komenda, Eric D Weinhandl, George L Bakris, Christopher T Chan, Richard J Fluck, John M Burkart
Although intensive hemodialysis (HD) can address important clinical problems, increasing treatment also introduces risks. In this review, we assess risks pertaining to 6 domains: vascular access complications, infection, mortality, loss of residual kidney function, solute balance, and patient and care partner burden. In the Frequent Hemodialysis Network (FHN) trials, short daily and nocturnal schedules increased the incidence of access complications, although the incidence of access loss was not statistically higher...
November 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/27772643/intensive-hemodialysis-left-ventricular-hypertrophy-and-cardiovascular-disease
#20
Peter A McCullough, Christopher T Chan, Eric D Weinhandl, John M Burkart, George L Bakris
The prevalence of cardiovascular disease, including cardiac arrhythmia, coronary artery disease, cardiomyopathy, and valvular heart disease, is higher in hemodialysis (HD) patients than in the US resident population. Cardiovascular disease is the leading cause of death in HD patients and the principal discharge diagnosis accompanying 1 in 4 hospital admissions. Furthermore, the rate of hospital admissions for either heart failure or fluid overload is persistently high despite widespread use of β-blockers and renin-angiotensin system inhibitors and attempts to manage fluid overload with ultrafiltration...
November 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
keyword
keyword
108629
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"